Refine
Year of publication
Document Type
- Article (8)
- Conference Proceeding (2)
Has Fulltext
- yes (10)
Is part of the Bibliography
- no (10)
Keywords
- acute myeloid leukemia (2)
- BCOR (1)
- BCORL1 (1)
- CVID (1)
- Clinical Trials and Observations (1)
- Die letzte Welt (1)
- European Society for Immunodeficiencies (ESID) (1)
- German PID-NET registry (1)
- Haematocrit (1)
- Heat shock protein 27 (1)
- IgG substitution therapy (1)
- Kinderhochzeit (1)
- Mean erythrocyte volume (1)
- Muschg, Adolf (1)
- Myeloid Neoplasia (1)
- Number of platelets (1)
- PID prevalence (1)
- Periodontitis grades B and C (1)
- Ransmayr, Christoph (1)
- cytarabine dose (1)
- elderly (1)
- loss-of-function (1)
- primary immunodeficiency (PID) (1)
- registry for primary immunodeficiency (1)
- risk stratification (1)
- survival (1)
A modern linear accelerator of ions is a long chain of different accelerating-focusing structures. The design of new linacs, as well as an upgrade and optimization of operating facilities, requires precise and reliable beam matching with the subsequent sections. Proper matching of the beam to the channel allows to improve the performance of the whole linac and to reduce the specific costs. Additionally it helps to avoide particle loss in high energy high intensity linacs. Generally a matching algorithm combines precisely measured or calculated accelerating-focusing external fields and experimentally obtained details of the beam parameters with an advanced code for beam dynamics simulations including space charge effects. Experimental results are introduced into a code as input data. The described algorithm has already been successfully implemented for several GSI projects: an upgrade of the GSI heavy ion linac UNILAC, an ion linac for the cancer therapy, the proton linac for the FAIR facility, a facility for laser acceleration of ions and others. Measured data and results of beam dynamics simulations leading to an achieved improvement of the linac performance are presented.
Mutations of the isocitrate dehydrogenase-1 (IDH1) and IDH2 genes are among the most frequent alterations in acute myeloid leukemia (AML) and can be found in ∼20% of patients at diagnosis. Among 4930 patients (median age, 56 years; interquartile range, 45-66) with newly diagnosed, intensively treated AML, we identified IDH1 mutations in 423 (8.6%) and IDH2 mutations in 575 (11.7%). Overall, there were no differences in response rates or survival for patients with mutations in IDH1 or IDH2 compared with patients without mutated IDH1/2. However, distinct clinical and comutational phenotypes of the most common subtypes of IDH1/2 mutations could be associated with differences in outcome. IDH1-R132C was associated with increased age, lower white blood cell (WBC) count, less frequent comutation of NPM1 and FLT3 internal tandem mutation (ITD) as well as with lower rate of complete remission and a trend toward reduced overall survival (OS) compared with other IDH1 mutation variants and wild-type (WT) IDH1/2. In our analysis, IDH2-R172K was associated with significantly lower WBC count, more karyotype abnormalities, and less frequent comutations of NPM1 and/or FLT3-ITD. Among patients within the European LeukemiaNet 2017 intermediate- and adverse-risk groups, relapse-free survival and OS were significantly better for those with IDH2-R172K compared with WT IDH, providing evidence that AML with IDH2-R172K could be a distinct entity with a specific comutation pattern and favorable outcome. In summary, the presented data from a large cohort of patients with IDH1/2 mutated AML indicate novel and clinically relevant findings for the most common IDH mutation subtypes.
The HITRAP linear decelerator currently being set up at GSI will provide slow, few keV/u highly charged ions for atomic physics experiments. The expected beam intensity is up to 105 ions per shot. To optimize phase and amplitude of the RF systems intensity, bunch length and kinetic energy of the particles need to be monitored. The bunch length that we need to fit is about 2 ns, which is typically measured by capacitive pickups. However, they do not work for the low beam intensities that we face. We investigated the bunch length with a fast CVD diamond detector working in single particle counting mode. Averaging over 8 shots yields a clear, regular picture of the bunched beam. Energy measurements by capacitive pickups are limited by the presence of intense primary and partially decelerated beam and hence make tuning of the IH-structure impossible. The energy of the decelerated fraction of the beam behind the first deceleration cavity was determined to about 10 % accuracy with a permanent dipole magnet combined with a MCP. Better detector calibration should help reaching the required 1%. Design of the detectors as well as the results of the measurements will be presented.
Aim: Assessment of the effect of nonsurgical periodontal therapy on haematological parameters in patients with grades B (BP) and C periodontitis (CP).
Methods: Eight BP and 46 CP patients received full-mouth periodontal debridement within 48 h, if positive for Aggregatibacter actinomycetemcomitans with adjunctive systemic antibiotics (4 BP, 17 CP). Clinical data were collected prior and 12 weeks after periodontal therapy. Blood was sampled prior to and 1 day as well as 6 and 12 weeks after the first SD visit. Erythrocyte count, haemoglobin value, haematocrit (HCT), mean erythrocyte volume (MCV), mean corpuscular haemoglobin (MCH), MCH concentration (MCHC), platelets (PLT) and heat shock protein 27 (Hsp27) were assessed.
Results: Both groups showed significant clinical improvement (p < 0.05). Using univariate analysis, MCV was noticeably lower in CP than BP at all examinations, HCT only at baseline. For CP, MCHC was noticeably higher 12 weeks after SD than at baseline and 1 day (p ≤ 0.005) and Hsp27 increased noticeably at 1 day (p < 0.05). Repeated measures analysis of variance revealed African origin to be associated with lower MCV and female sex with lower MCHC.
Conclusion: Based on multivariate analysis, periodontal diagnosis (BP/CP) was not associated with haematological parameters measured in this study or serum Hsp27. In CP, nonsurgical periodontal therapy improved MCHC 12 weeks after SD. Also in CP Hsp27 was increased 1 day after SD.
Adolf Muschgs "Kinderhochzeit" liegt wie ein unübersichtliches Gebirgsmassiv im literarischen Gelände. Der Roman ist ein Alterswerk und zugleich die Eröffnung eines völlig neuen Kapitels; die Summe einer vieljährigen Autorschaft, und doch ungleich mehr als die verbreiterte Strömung seiner erprobten Erzählkunst. Sie bewährt sich auch hier, aber indem sie sich abarbeitet an einem widerständigen, in seinen Elementen auseinanderstrebenden, hoch brisanten und aktuellen Stoff. Muschg schmilzt Geschichte und Geistesgeschichte längst vergangener Jahrhunderte in Biographien und Erfahrungswelten ein, die sich zwischen Hitlerherrschaft und globalisierter Gegenwart erstrecken. Ein dichtes, zuweilen angestrengtes Spiel der Verweisungen bis in entlegene Bildungsstoffe und ins eigene frühere Werk durchzieht den Text, der sich einer Fülle epischer Darstellungsmöglichkeiten bedient.
Christian Lehnerts Libretto zu Hans Werner Henzes Oper "Phaedra" endet im Bild eines Vogels, der sich am Widerstand des Todes wie an einem Aufwind emporschraubt, kreisend und singend "wilder als alles Vergängliche". Er ist Symbol der Kunst, die ungebrochen und unbrechbar die Kraft hat, Versöhnungsbilder des Menschen mit sich und seiner Welt hervorzubringen. Etwa 20 Jahre zuvor läuft Christoph Ransmayrs 1988 erschienener Roman "Die letzte Welt" in die Vision einer aufblühenden Welt aus, und zwei entsetzlich erniedrigte junge Frauen sowie ihr blutdurstiger Verfolger schwingen sich - im Augenblick der zum Mord geschwungenen Axt verwandelt in Nachtigall, Schwalbe und Wiedehopf - als Vögel in einen "nachtblauen Himmel" (S. 284). Ransmayr zitiert in diesem Aufschwung eine Episode aus den "Metamorphosen" des römischen Klassikers der Augusteischen Zeit, Ovid. Damit stellt er sich in eine große Tradition, denn diese Dichtung diente dem Mittelalter als Kompendium des mythologischen und historischen Wissens der Antike, und auch später bediente sich die europäische Weltliteratur immer wieder aus diesem Fundus, der die Masse und Vielfalt der griechischen und römischen Mythen und anderes Erzählgut verschiedener Herkunft und literarischer Ausprägung spätzeitlich zusammenfasste und organisierte.
Introduction: The German PID-NET registry was founded in 2009, serving as the first national registry of patients with primary immunodeficiencies (PID) in Germany. It is part of the European Society for Immunodeficiencies (ESID) registry. The primary purpose of the registry is to gather data on the epidemiology, diagnostic delay, diagnosis, and treatment of PIDs.
Methods: Clinical and laboratory data was collected from 2,453 patients from 36 German PID centres in an online registry. Data was analysed with the software Stata® and Excel.
Results: The minimum prevalence of PID in Germany is 2.72 per 100,000 inhabitants. Among patients aged 1–25, there was a clear predominance of males. The median age of living patients ranged between 7 and 40 years, depending on the respective PID. Predominantly antibody disorders were the most prevalent group with 57% of all 2,453 PID patients (including 728 CVID patients). A gene defect was identified in 36% of patients. Familial cases were observed in 21% of patients. The age of onset for presenting symptoms ranged from birth to late adulthood (range 0–88 years). Presenting symptoms comprised infections (74%) and immune dysregulation (22%). Ninety-three patients were diagnosed without prior clinical symptoms. Regarding the general and clinical diagnostic delay, no PID had undergone a slight decrease within the last decade. However, both, SCID and hyper IgE- syndrome showed a substantial improvement in shortening the time between onset of symptoms and genetic diagnosis. Regarding treatment, 49% of all patients received immunoglobulin G (IgG) substitution (70%—subcutaneous; 29%—intravenous; 1%—unknown). Three-hundred patients underwent at least one hematopoietic stem cell transplantation (HSCT). Five patients had gene therapy.
Conclusion: The German PID-NET registry is a precious tool for physicians, researchers, the pharmaceutical industry, politicians, and ultimately the patients, for whom the outcomes will eventually lead to a more timely diagnosis and better treatment.
Background: The combination of intermediate-dose cytarabine plus mitoxantrone (IMA) can induce high complete remission rates with acceptable toxicity in elderly patients with acute myeloid leukemia (AML). We present the final results of a randomized-controlled trial comparing IMA with the standard 7 + 3 induction regimen consisting of continuous infusion cytarabine plus daunorubicin (DA).
Patients and methods: Patients with newly diagnosed AML >60 years were randomized to receive either intermediate-dose cytarabine (1000 mg/m2 twice daily on days 1, 3, 5, 7) plus mitoxantrone (10 mg/m2 days 1–3) (IMA) or standard induction therapy with cytarabine (100 mg/m2 continuously days 1–7) plus daunorubicin (45 mg/m2 days 3–5) (DA). Patients in complete remission after DA received intermediate-dose cytarabine plus amsacrine as consolidation treatment, whereas patients after IMA were consolidated with standard-dose cytarabine plus mitoxantrone.
Results: Between February 2005 and October 2009, 485 patients were randomized; 241 for treatment arm DA and 244 for IMA; 76% of patients were >65 years. The complete response rate after DA was 39% [95% confidence interval (95% CI): 33–45] versus 55% (95% CI: 49–61) after IMA (odds ratio 1.89, P = 0.001). The 6-week early-death rate was 14% in both arms. Relapse-free survival curves were superimposable in the first year, but separated afterwards, resulting in 3-year relapse-free survival rates of 29% versus 14% in the DA versus IMA arms, respectively (P = 0.042). The median overall survival was 10 months in both arms (P = 0.513).
Conclusion: The dose escalation of cytarabine in induction therapy lead to improved remission rates in the elderly AML patients. This did not translate into a survival advantage, most likely due to differences in consolidation treatment. Thus, effective consolidation strategies need to be further explored. In combination with an effective consolidation strategy, the use of intermediate-dose cytarabine in induction may improve curative treatment for elderly AML patients.
Simple Summary: Acute myeloid leukemia (AML) is a genetically heterogeneous disease. Clinical phenotypes of frequent mutations and their impact on patient outcome are well established. However, the role of rare mutations often remains elusive. We retrospectively analyzed 1529 newly diagnosed and intensively treated AML patients for mutations of BCOR and BCORL1. We report a distinct co-mutational pattern that suggests a role in disease progression rather than initiation, especially affecting mechanisms of DNA-methylation. Further, we found loss-of-function mutations of BCOR to be independent markers of poor outcomes in multivariable analysis. Therefore, loss-of-function mutations of BCOR need to be considered for AML management, as they may influence risk stratification and subsequent treatment allocation.
Abstract: Acute myeloid leukemia (AML) is characterized by recurrent genetic events. The BCL6 corepressor (BCOR) and its homolog, the BCL6 corepressor-like 1 (BCORL1), have been reported to be rare but recurrent mutations in AML. Previously, smaller studies have reported conflicting results regarding impacts on outcomes. Here, we retrospectively analyzed a large cohort of 1529 patients with newly diagnosed and intensively treated AML. BCOR and BCORL1 mutations were found in 71 (4.6%) and 53 patients (3.5%), respectively. Frequently co-mutated genes were DNTM3A, TET2 and RUNX1. Mutated BCORL1 and loss-of-function mutations of BCOR were significantly more common in the ELN2017 intermediate-risk group. Patients harboring loss-of-function mutations of BCOR had a significantly reduced median event-free survival (HR = 1.464 (95%-Confidence Interval (CI): 1.005–2.134), p = 0.047), relapse-free survival (HR = 1.904 (95%-CI: 1.163–3.117), p = 0.01), and trend for reduced overall survival (HR = 1.495 (95%-CI: 0.990–2.258), p = 0.056) in multivariable analysis. Our study establishes a novel role for loss-of-function mutations of BCOR regarding risk stratification in AML, which may influence treatment allocation.